Insmed (INSM) Investor presentation summary

Strategic focus and therapeutic areas

• Pursues first- and best-in-class therapies across respiratory, immunology & inflammation, and neuro/rare diseases, with a robust pipeline spanning all development phases.

• Key assets include BRINSUPRI (brensocatib) for bronchiectasis and HS, ARIKAYCE for MAC lung disease, and TPIP for PAH and PH-ILD.

• Pipeline also features gene therapies for DMD, ALS, Stargardt disease, and antisense oligonucleotide programs for rare neurodegenerative disorders.

Commercial and clinical catalysts

• Multiple commercial and clinical milestones expected in the next 18+ months, including U.S. launch and expansion of BRINSUPRI and ARIKAYCE label expansion.

• Anticipated clinical readouts and trial initiations in respiratory, immunology, and neuro/rare disease programs.

• Business development activities and new IND filings planned to support future growth.

Financial outlook and performance

• 2026 revenue guidance: BRINSUPRI at least $1B (mid-20% to low-30% gross-to-net), ARIKAYCE $450M–$470M (low-20% to mid-20% gross-to-net).

• BRINSUPRI achieved ~$144.6M U.S. net revenues in Q4 2025, surpassing comparable respiratory launches.

• ARIKAYCE posted $433.8M worldwide revenue in FY 2025, with strong growth in both U.S. and international markets.